Hence, low niacin levels, lack of de novo synthesis genes, and selective silencing of NAPRT1 in cancer cells inhibiting the NAMPT pathway create the necessary vulnerability to inhibit cancer cell growth. This evidence concerns the gene NAMPT and cancer.